Findings

What do systematic reviews say?

2 questions · 2 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 100%High 0 · 0%

Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) vs ADT only

Death (all causes)

Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) probably leads to lower time to death due to any cause (absolute effect size estimates based… compared with ADT only (moderate certainty).

1 finding from 1 review

Taxane‐based chemohormonal therapy for metastatic hormone‐sensitive prostate cancer 2018 · Cochrane Headline outcomes only
HR 0.77 [0.68, 0.87]
3 studies · 2261 participants
Moderate

Early vs deferred AST

Time to death from any cause (here: overall mortality at 12‐month · advanced hormone‐sensitive prostate cancer

Early probably leads to lower time to death of any cause (here: all‐cause mortality at 5 years) compared with deferred AST (moderate certainty).

1 finding from 1 review

Early versus deferred standard androgen suppression therapy for advanced hormone‐sensitive prostate cancer 2019 · Cochrane Headline outcomes only
HR 0.82 [0.75, 0.9]
10 studies · 4767 participants
Moderate